Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLYMPIA-1: Odronextamab versus rituximab plus chemotherapy in previously untreated follicular lymphoma
MOH_2023-10-18_012992Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of odronextamab in follicular lymphoma (FL) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Safety and tolerability and Comparative efficacy. Started Sep 2023; status: recruiting.
02
Drugs
odronextamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on MOH_2023-10-18_012992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-18_012992.